Showing 20 of 136 recruiting trials for “plasmablastic-lymphoma”
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
👨⚕️ Wang Sanbin, MD, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China📍 1 site📅 Started Jul 2025View details ↗
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
RecruitingNCT07326930 ↗
Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
👨⚕️ Vironexis Clinical Trials, Vironexis Biotherapeutics Inc.📍 9 sites📅 Started May 2025View details ↗
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
👨⚕️ Aimee Talleur, MD, St. Jude Children's Research Hospital📍 1 site📅 Started May 2025View details ↗
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
👨⚕️ Caroline Diorio, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Apr 2025View details ↗
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
👨⚕️ Yue-jun Liu, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2025View details ↗
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
👨⚕️ Joseph McGuirk, D.O., University of Kansas Medical Center📍 1 site📅 Started Mar 2025View details ↗
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
👨⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
Newly-diagnosed Pediatric T-cell ALL Protocol
👨⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
👨⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
👨⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →